La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Halozyme Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Halozyme Therapeutics does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	US$2.66
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Aug 14

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if HALO's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if HALO's dividend payments have been increasing.

Rendimento dei dividendi rispetto al mercato

Halozyme Therapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di HALO rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (HALO)	n/a
Fondo del 25% del mercato (US)	1.5%
Top 25% del mercato (US)	4.4%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (HALO)	n/a

Dividendo notevole: Unable to evaluate HALO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate HALO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate HALO's payout ratio to determine if its dividend payments are covered by earnings.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as HALO has not reported any payouts.

Halozyme Therapeutics Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Independent Director recently sold US$1.7m worth of stock

Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals

Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Senior VP & CTO notifies of intention to sell stock

Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar

Senior VP & CFO notifies of intention to sell stock

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics: The Story Brightens

Investor sentiment improves as stock rises 19%

Senior VP & CTO exercised options and sold US$743k worth of stock

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Senior VP & Chief Technical Officer notifies of intention to sell stock

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Insufficient new directors

Price target decreased by 7.1% to US$52.11

Investor sentiment deteriorates as stock falls 16%

President notifies of intention to sell stock

Independent Director recently sold US$962k worth of stock